Grant: Project Grant
University of Toronto
$864,450.00
SUMO-Modulating Proteins of Epstein-Barr Virus
FY 2018-19
Summary
Epstein-Barr virus (EBV) is a herpesvirus that infects most people and is a causative agent for mononucleosis, oral hairy leukoplakia and several types of cancer, accounting for 200,000 new cancer cases and 140,000 deaths per year. EBV encodes many proteins to promote life-long infection. We have performed proteomic screens whose functions are not known but are believed to manipulate cells for EBV proteins that affect cellular protein modifications that are central to antiviral responses and cancer. We identified three EBV proteins (SM, BMRF1 and BRLF1) that have dramatic effects on these cellular modifications. This project will determine the mechanisms of action and functional consequences of these EBV protein activities, including how they impact EBV infection and cancer-associated pathways. The novel activities of these EBV proteins provide new therapeutic opportunities to inhibit EBV infection.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
389410
Name
Frappier Lori D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
SUMO-Modulating Proteins of Epstein-Barr Virus
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$864,450
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Bmrf1; Brlf1; Epstein-Barr Virus; Sm; Sumo Ligase; Sumoylation
Abstract
Epstein-Barr virus (EBV) is a herpesvirus that infects most people and is a causative agent for mononucleosis, oral hairy leukoplakia and several types of cancer, accounting for 200,000 new cancer cases and 140,000 deaths per year. EBV encodes many proteins to promote life-long infection. We have performed proteomic screens whose functions are not known but are believed to manipulate cells for EBV proteins that affect cellular protein modifications that are central to antiviral responses and cancer. We identified three EBV proteins (SM, BMRF1 and BRLF1) that have dramatic effects on these cellular modifications. This project will determine the mechanisms of action and functional consequences of these EBV protein activities, including how they impact EBV infection and cancer-associated pathways. The novel activities of these EBV proteins provide new therapeutic opportunities to inhibit EBV infection.
Competitiondate
201809
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Frappier, Lori D
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $864,450~ $0~
